Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Work
Year: 2019
Type: article
Abstract: Patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who have disease progression after therapy with multiple HER2-targeted agents have limited treatment opt... more
Source: New England Journal of Medicine
Institutions The University of Texas MD Anderson Cancer Center, Peter MacCallum Cancer Centre, Royal Marsden NHS Foundation Trust, Piedmont Cancer Institute, Winship Cancer Institute +31 more
Cites: 28
Cited by: 1,047
Related to: 10
FWCI: 74.43
Citation percentile (by year/subfield): 87.85
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: bronze
Funder Seattle Genetics